Issue Date: June 13, 2016
Ixaltis gets funds to repurpose drug
Ixaltis, a start-up company focused on urogenital disorders, has raised $9 million in its first funding round. The French firm’s pipeline consists of three compounds licensed from Sanofi. The most advanced is litoxetine, a serotonin reuptake inhibitor and 5-HT3 receptor antagonist that Sanofi had studied as an antidepressant. Ixaltis will soon begin testing the compound in a Phase II trial for treating urinary incontinence. The company also received a $3.2 million loan under an academic-industrial . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society